16 employees
ImmVirX devolops novel oncolytic viruses to create powerful new cancer immunotherapy combinations.
2019
$25M
from 3 investors over 3 rounds
ImmVirX raised $25M on June 5, 2023
Investors: Acorn Capital Ltd and OneVentures
ImmVirX raised $22M on May 14, 2021
Investors: Acorn Capital Ltd